in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance.
.
.
.
�the kind of review being proposed does not, at least initially, appear to bring anything new or needed to is already a robust system of oversight,� mogulof said in the statement.
.
.imagine a congressional hearing held before media cameras, with reporters all over the us and europe ready with shocking articles about one of the leading causes of death�
.
.
.